PD-1 inhibitor plus anti-angiogenic tablet in recurrent nasopharyngeal carcinoma: promising, with a necrosis risk

Design

Systematic review and single-arm meta-analysis of phase 2 trials and retrospective cohorts

Population

357 patients with recurrent or metastatic nasopharyngeal carcinoma across 10 cohorts

Primary outcome

Objective response rate, disease control rate, 1-year survival and toxicity

Effect

ORR 48% (95% CI 39% to 57%); DCR 83% (77% to 88%); grade 3 or higher adverse events 47% (37% to 58%)

This single-arm meta-analysis pooled 10 cohorts (357 patients) from nine studies of a PD-1 or PD-L1 inhibitor combined with apatinib, anlotinib or famitinib in recurrent or metastatic nasopharyngeal carcinoma. They were mostly phase 2 trials and retrospective cohorts.

Pooled objective response was 48% (95% CI 39% to 57%), disease control 83% (77% to 88%) and one-year overall survival 79% (68% to 86%). Grade 3 or higher treatment-related adverse events occurred in 47% (37% to 58%), most often nasopharyngeal necrosis (14%), hand-foot syndrome (10%) and hypertension (9%). Nasopharyngeal necrosis needs close monitoring because of the risk of severe bleeding. No treatment-related deaths were reported. Patients who had not had immunotherapy before responded more often than those who had (P = 0.0028).

No comparison with standard therapy was possible, since pooled single-arm studies cannot show that the combination beats a PD-1 inhibitor with chemotherapy. The authors call for randomised trials. The drug combination is mostly studied in China, and availability in India varies.

• Consider this as an area for trials or specialist tumour board discussion, not a standard second-line option.
• Monitor blood pressure, skin and nasopharyngeal symptoms on any anti-angiogenic combination.
• Ask patients about bleeding, pain or discharge from the nasopharynx; necrosis can bleed severely.
• Record previous immunotherapy, since response differed by prior exposure.

Why it matters

It gathers early evidence for a combination being tried in a disease where options after progression are limited.

Don't overread it

Pooled single-arm and retrospective data cannot show superiority over standard therapy; the abstract itself calls for randomised trials.

The statistics, in plain English

A pooled response rate of 48% from single-arm studies tells you what proportion responded, not whether the response is better than other treatments, because there is no comparison group. A 47% rate of serious toxicity means about half of patients had a grade 3 or higher event.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.